SciSparc Ltd

Contributing Author

Recent Articles by SciSparc Ltd

Sep-02	SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies SPRC GlobeNewswire
Aug-31	SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI-210 Autism Clinical Trial SPRC SPRC -14.48% GlobeNewswire
Aug-26	SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board SPRC GlobeNewswire
Aug-24	SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation SPRC GlobeNewswire
Aug-18	SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million SPRC GlobeNewswire
Aug-12	SciSparc's Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination SPRC GlobeNewswire
Aug-05	SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome SPRC GlobeNewswire
Jul-31	SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics SPRC -18.16% GlobeNewswire
Jul-29	SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company SPRC +70.54% GlobeNewswire
Jul-27	SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity SPRC -6.00% GlobeNewswire
Jul-15	SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome SPRC +14.75% GlobeNewswire
Jun-04	SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum SPRC +21.99% GlobeNewswire
May-28	SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum SPRC +140.32% GlobeNewswire
Mar-16	SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy SPRC GlobeNewswire
Mar-12	SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease SPRC +22.86% GlobeNewswire
Mar-10	SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails SPRC -28.34% GlobeNewswire
Mar-02	SciSparc Announces 1-for-9 Reverse Share Split SPRC -9.87% GlobeNewswire
Feb-02	SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA SPRC GlobeNewswire
Jan-26	SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization SPRC -7.92% GlobeNewswire
Jan-13	SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity SPRC -15.52% GlobeNewswire
Jan-12	SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance SPRC GlobeNewswire
Dec-30	SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects SPRC GlobeNewswire
Dec-02	SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company SPRC GlobeNewswire
Dec-01	SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio SPRC -16.36% GlobeNewswire
Nov-26	SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems SPRC -9.02% GlobeNewswire
Nov-20	SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression SPRC GlobeNewswire
Oct-24	SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio SPRC GlobeNewswire
Oct-23	SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer SPRC GlobeNewswire
Oct-23	SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery SPRC GlobeNewswire
Oct-20	SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders SPRC +12.83% GlobeNewswire
Oct-15	SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio SPRC +24.35% GlobeNewswire
Oct-06	SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors SPRC GlobeNewswire
Sep-29	SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer SPRC SPRC +35.43% GlobeNewswire
Sep-25	SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery SPRC +59.01% GlobeNewswire
Aug-28	SciSparc: AutoMax's Shareholders Approve Merger with SciSparc SPRC -28.87% GlobeNewswire
Aug-28	SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel SPRC -28.87% GlobeNewswire
Aug-07	SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar SPRC GlobeNewswire
Jul-30	SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC SPRC -6.13% SPRC -8.92% GlobeNewswire
Jul-30	SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease SPRC -6.13% GlobeNewswire
Jul-22	SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification SPRC GlobeNewswire
Jun-24	SciSparc Announces 1-for-21 Reverse Share Split SPRC +5.80% GlobeNewswire
May-27	SciSparc Announces Publication of Japanese Patent Application SPRC GlobeNewswire
May-12	SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction SPRC GlobeNewswire

SciSparc Ltd

Recent Articles by SciSparc Ltd

Upgrade your Finviz experience